Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
BARCELONA, Jul 28, 2023 – (ACN Newswire) – Peptomyc S.L., a biotech company specialized in…
BARCELONA, Jul 28, 2023 – (ACN Newswire) – Peptomyc S.L., a biotech company specialized in…
– First Quarter Fiscal 2024 Revenues of $416 million – – First Quarter Fiscal 2024…
Declares increase to third quarter 2023 common stock dividend Company Highlights Second quarter 2023 net…
MILL VALLEY, Calif.–(BUSINESS WIRE)–Redwood Trust, Inc. (NYSE:RWT; “Redwood” or the “Company”), a leader in expanding…
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties, Inc. (NYSE: LTC) (“LTC” or the “Company”), a real estate…
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its…
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in…
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million…
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit…
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–PennyMac Mortgage Investment Trust (NYSE: PMT) today reported net income attributable to…
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team…
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS-…
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
PRESS RELEASE PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split…
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS,…
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Announced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial Evaluating HMI-103 BEDFORD,…
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a leading…
Vancouver, British Columbia–(Newsfile Corp. – July 27, 2023) – The Company (TSXV: SVS) is very…